Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 0.92 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.92 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.92 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.92 |
| ▸ | NSD2 | O96028 | 1/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.92 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.92 |
| ▸ | BID | P55957 | 1/20 | 0.92 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.92 |
| ▸ | ASPH | Q12797 | 1/20 | 0.92 |
| ▸ | BAD | Q92934 | 1/20 | 0.92 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.92 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.92 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16038769 | 0.96 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038376 | 0.96 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29801595 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699874 | 0.96 | BCL2 (0.91) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29390802 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699923 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699927 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16160643 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL523816 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29353714 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793802-B2 | Treatment of acute myeloid leukemia (AML) with venetoclax failure | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230312566-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230255959-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11718611-B2 | Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230226045-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20180207164-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180140700-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180117052-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | Kronos Bio, Inc. | 2018-05-03 | — | — | US | disclosed |
| US-20180065961-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES | 2018-03-08 | — | — | US | disclosed |
| US-9840502-B2 | Salts and crystalline forms of an apoptosis-inducing agent | ABBVIE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160083384-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES | 2016-03-24 | — | — | US | disclosed |
| US-9238649-B2 | Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | ABBVIE INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9199992-B2 | Processes for the preparation of an apoptosis-inducing agent | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150183783-A1 | PROCESSES FOR THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. | 2015-07-02 | — | — | US | disclosed |
| US-9006438-B2 | Processes for the preparation of an apoptosis-inducing agent | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140275540-A1 | Processes For The Preparation Of An Apoptosis-Inducing Agent | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140248262-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140213596-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8722657-B2 | Salts and crystalline forms of an apoptosis-inducing agent | ABBVIE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120157470-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718611-B2 | Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885BCL2L1 2/4885MCL1 16/4885 |
| US-20180117052-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | MCL1, BCL2, BAK1 | BCL2 2/4885BCL2L1 10/4885MCL1 1/4885 |
| US-20230312566-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | BCL2 1/4885BCL2L1 5/4885MCL1 23/4885 |
| US-20180065961-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | BCL2 1/4885BCL2L1 5/4885MCL1 23/4885 |
| US-20180140700-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2 4/4885BCL2L1 6/4885MCL1 22/4885 |
| US-11793802-B2 | Treatment of acute myeloid leukemia (AML) with venetoclax failure | MCL1, DNMT3A, NSD1 | BCL2 794/4885BCL2L1 1408/4885MCL1 1/4885 |
| US-20120157470-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | BCL2 1/4885BCL2L1 5/4885MCL1 23/4885 |
| US-20180207164-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BTK, SYK, BCL3 | BCL2 20/4885BCL2L1 17/4885MCL1 13/4885 |
| US-20230255959-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
| US-20150183783-A1 | PROCESSES FOR THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | BAX, AIFM1, BAD | BCL2 4/4885BCL2L1 25/4885MCL1 12/4885 |
| US-20140248262-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
| US-20140213596-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | BCL2 1/4885BCL2L1 5/4885MCL1 23/4885 |
| US-20140275540-A1 | Processes For The Preparation Of An Apoptosis-Inducing Agent | BAX, AIFM1, BAD | BCL2 4/4885BCL2L1 25/4885MCL1 12/4885 |
| US-20160083384-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | BCL2 1/4885BCL2L1 5/4885MCL1 23/4885 |
| US-20230226045-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.